Lord, Abbett & Co
JANX icon

Lord, Abbett & Co’s Janux Therapeutics JANX Stock Holding History

Lord, Abbett & Co’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-667,881
Closed -$18M – 550
2025
Q1 		$18M Sell
667,881
-599,922
-47% -$22.6M 0.06% 296
2024
Q4 		$67.9M Buy
1,267,803
+564,322
+80% +$29.8M 0.21% 129
2024
Q3 		$32M Buy
703,481
+874
+0.1% +$38K 0.1% 246
2024
Q2 		$29.4M Buy
702,607
+160,234
+30% +$7.52M 0.1% 251
2024
Q1 		$20.4M Buy
+542,373
New +$11.8M 0.07% 331

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Lord, Abbett & Co's JANX Position: Q2 2025 in Review

Lord, Abbett & Co sold out of Janux Therapeutics (JANX) in Q2 2025, closing a stake of 667,881 shares — an estimated $18M sold.

Lord, Abbett & Co first reported a position in JANX in Q1 2024 and held it in 5 quarters. The position peaked at $67.9M in Q4 2024. 174 funds tracked by Wall St. Rank hold JANX as of Q2 2025.

  • Lord, Abbett & Co reported no remaining Janux Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Lord, Abbett & Co sold 667,881 Janux Therapeutics shares in Q2 2025, an estimated $18M.
  • Lord, Abbett & Co first reported a position in Janux Therapeutics in Q1 2024 and held it in 5 quarters.
  • Lord, Abbett & Co's Janux Therapeutics position peaked at $67.9M in Q4 2024.
  • 174 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2025.

Based on Lord, Abbett & Co's 13F filing for Q2 2025, filed 14 Aug 2025.